Vaishali Pharma enterprise value

·UnclassifiedChart ›

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023


44.5	—	—	—	—
1.1	1.1	1.7	1.5	0.5
18.5	18.5	11.7	12.6	13.7
61.9	—	—	—	—
17.4	17.4	9.9	11.2	13.1
₹9.49	—	—	—	—

87.6	87.6	76.6	55.4	54.2
21.1%	21.1%	15.2%	22.7%	25.2%
0.30×	—	—	—	—

0.57×	—	—	—	—
14.63×	—	—	—	—
17.02×	—	—	—	—
108	109	—	—	—
4.2	4.1	—	—	—
3.6	3.5	—	—	—
—	0.4	−18.0	—	1.1
−0.0	−0.0	−18.0	—	1.1
—	0.3	—	—	—
—	0.5	—	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VAISHALI₹6.82

Vaishali Pharma Limited

· Unclassified

₹ CrorePeersTEMBO TOTAL OSWALSEEDS GROBTEA BEARDSELL HINDCON CROWN ARTNIRMANMcap ₹44.5 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	44.5
- Cash, Equiv & ST Investments	0.5	1.5	1.7	1.1	1.1
+ Total Debt	13.7	12.6	11.7	18.5	18.5
Enterprise Value	—	—	—	—	61.9
Net Debt (memo)	13.1	11.2	9.9	17.4	17.4
EV per Share	—	—	—	—	9.49

Total Capital	54.2	55.4	76.6	87.6	87.6
Total Debt/Total Capital	25.21	22.74	15.23	21.14	21.14
Total Debt/EV	—	—	—	—	0.30

EV/Sales	—	—	—	—	0.57
EV/EBITDA	—	—	—	—	14.63
EV/EBIT	—	—	—	—	17.02
Reference Items — Trailing FY Values
Sales	—	—	—	108.8	107.9
EBITDA	—	—	—	4.1	4.2
EBIT	—	—	—	3.5	3.6
Operating Cash Flow	1.1	—	-18.0	0.4	—
Free Cash Flow	1.1	—	-18.0	-0.0	-0.0
FCFF (free cash flow to the firm)	—	—	—	0.3	—
Capital Expenditure	—	—	—	0.5	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.